Faheem Hasnain gets a $212M stake together for his big PhIII gamble — here’s why investors are letting it ride

Faheem Hasnain has his back against the wall — but he isn’t about to quit now.

Bioregnum Opinion Column by John Carroll

This morning the Gossamer CEO is taking the wraps off a $212 million private placement to pay for a Phase III study he…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks